Artificial intelligence (AI) software company Viz.ai raised $100 million in a recent funding round to support its growth and expand its AI platform to detect and triage additional diseases.
Over the past year, Viz.ai has launched AI-driven software for helping diagnose aortic disease, pulmonary embolism, and cerebral aneurysms, and it has a product pending 510(k) clearance for subdural hematoma.
The company received its first five CE Marks in 2021, followed by contracts with several leading hospitals. The number of hospitals using the Viz Platform recently surpassed the 1,000 mark, Viz.ai said. The company added that it has grown from 180 employees to more than 350 over the past 12 months, and it is planning to grow by nearly 200 people over the next 12 months.
Tiger Global and Insight Partners led the funding round, joined by several of Viz.ai's early backers.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
